Pre-Clinical Autoimmunity in Lupus Relatives: Self-Reported Questionnaires and Immune Dysregulation Distinguish Relatives Who Develop Incomplete or Classified Lupus From Clinically Unaffected Relatives and Unaffected, Unrelated Individuals

Systemic lupus erythematosus (SLE) is propelled by pathogenic autoantibody (AutoAb) and immune pathway dysregulation. Identifying populations at risk of reaching classified SLE is essential to curtail inflammatory damage. Lupus blood relatives (Rel) have an increased risk of developing SLE. We teste...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2022-06, Vol.13, p.866181-866181
Main Authors: Munroe, Melissa E., Young, Kendra A., Guthridge, Joel M., Kamen, Diane L., Gilkeson, Gary S., Weisman, Michael H., Ishimori, Mariko L., Wallace, Daniel J., Karp, David R., Harley, John B., Norris, Jill M., James, Judith A.
Format: Article
Language:English
Subjects:
autoantibodies
autoimmunity
cytokines
family studies
Immunology
pre-clinical disease
systemic lupus erythematosus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic lupus erythematosus (SLE) is propelled by pathogenic autoantibody (AutoAb) and immune pathway dysregulation. Identifying populations at risk of reaching classified SLE is essential to curtail inflammatory damage. Lupus blood relatives (Rel) have an increased risk of developing SLE. We tested factors to identify Rel at risk of developing incomplete lupus (ILE) or classified SLE vs. clinically unaffected Rel and healthy controls (HC), drawing from two unique, well characterized lupus cohorts, the lupus autoimmunity in relatives (LAUREL) follow-up cohort, consisting of Rel meeting
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.866181